This increased demand can potentially create relative deficiencies in these co-factors, even if their levels were previously adequate
This absence of IGF-1 stimulation has been consistently demonstrated across multiple studies and dose ranges
The retatrutide versus semaglutide comparison highlights just how much more aggressive the weight loss trajectory may be, which could have implications for how aggressively providers prescribe to patients at lower BMI ranges
The other side of the coin, however, as you're getting to, is who wants another disease
Your provider can help you manage these effects by adjusting your dose or offering guidance on diet and hydration
Diabetology & metabolic syndrome 3 , 31, doi:10.1186/1758-5996-3-31 (2011)